2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
W

2020 ASCO Update on Melanoma: Does Ipilimumab + PD-1 Have a Higher RR and OS vs. Ipilimumab Alone in Patients Resistant to PD-1?

By 2020 ASCO Virtual Direct™ Highlights FEATURING William Sharfman
By 2020 ASCO Virtual Direct™ Highlights FEATURING William Sharfman
36 views
July 17, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

20:09
AstraZeneca Oncology

Management Strategies for Anemia in First-line Maintenance Therapy f…

Feat. D. Czel, C. Arn

Featured Video

21:09
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam
Skin
06:56
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Stage III Melanoma: Does Pembrolizumab Improve R…

Feat. W. Sharfman
06:53
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Resected Stage III BRAF V600-mutant Melanoma: Is…

Feat. W. Sharfman
09:16
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Melanoma: Is There Significant Antitumor Activit…

Feat. W. Sharfman
10:12
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Melanoma: Does Ipilimumab + PD-1 Have a Higher R…

Feat. W. Sharfman
08:08
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Stage IV Melanoma: Is Lifileucel Effective and D…

Feat. W. Sharfman